Recordati Acquires Sanofi's Rare Disease Drug Enjaymo for $825M, Expanding Global Reach
Recordati's $825 million investment in Enjaymo represents a strategic expansion in the rare disease sector, building on its focus in this niche market[1][2]. Enjaymo, currently the only FDA-approved treatment for hemolysis in cold agglutinin disease (CAD), is expected to enhance Recordati's presence across the U.S., Europe, and Japan[1]. The acquisition is financed through cash and new bank debt facilities, and Recordati anticipates the drug's revenue could peak between 250 million to 300 million euros by 2025[2].
References
Explore Further
What are the potential milestone payments included in Recordati's acquisition deal for Enjaymo?
How does the acquisition of Enjaymo align with Recordati's broader strategic objectives in the rare disease sector?
What specific challenges has Enjaymo faced in its journey through multiple ownership changes?
How will Recordati's financing of the acquisition impact its financial strategy and market positioning?
What are Sanofi's plans for reinvesting the proceeds from the divestment of Enjaymo into its core focus areas like immunology?